Literature DB >> 10890988

Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus.

D Ioannides1, F Chrysomallis, J C Bystryn.   

Abstract

OBJECTIVE: To compare the effectiveness and the adverse effects of 2 different regimens for the treatment of pemphigus: corticosteroids alone compared with a combination of corticosteroids and cyclosporine.
DESIGN: Concurrently randomized trial.
SETTING: Tertiary care medical center. PATIENTS AND METHODS: We studied 33 sequential hospitalized patients with newly diagnosed pemphigus vulgaris (n=29) or pemphigus foliaceous (n=4) based on clinical, histological, and immunofluorescence criteria who had not previously been treated with systemic corticosteroids or immununosuppressive drugs. Patients were randomly assigned to treatment with methylprednisolone or prednisolone plus cyclosporine. INTERVENTION: Both groups were treated with similar initial doses of prednisolone (prednisone equivalent, 1 mg/kg), which were increased 50% every 5 to 10 days based on persistence of disease activity. One group was treated in addition with cyclosporine (5 mg/kg). MAIN OUTCOME MEASURES: Patients were followed up closely for clinical outcome based on time required to control active manifestations of the disease, induction of partial and complete remissions, total amount of corticosteroids administered, frequency of relapses, and development of complications.
RESULTS: The 2 groups were similar in terms of demographics and baseline disease severity. There was no difference between groups in any of the variables used to measure response to treatment or total amount of corticosteroids administered. Complications were more common in patients who received combination therapy.
CONCLUSION: Combination treatment with corticosteroids and cyclosporine, 5 mg/kg, offers no advantage over treatment with corticosteroids alone in patients with pemphigus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890988     DOI: 10.1001/archderm.136.7.868

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  10 in total

Review 1.  Intravenous immunoglobulin for treatment of pemphigus.

Authors:  Lehavit Akerman; Daniel Mimouni; Michael David
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  Pemphigus.

Authors:  Michael Kasperkiewicz; Christoph T Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Aimee S Payne; Masayuki Amagai
Journal:  Nat Rev Dis Primers       Date:  2017-05-11       Impact factor: 52.329

3.  [Gold. Effective therapy for mucosal lesions of pemphigus vulgaris].

Authors:  D Lange; F Meiss; E Fiedler; K Treiber; W C Marsch; M Fischer
Journal:  Hautarzt       Date:  2007-02       Impact factor: 0.751

4.  Survival of Adjuvant Drugs for Treatment of Pemphigus: A Population-based Cohort Study.

Authors:  Khalaf Kridin; Christoph M Hammers; Ralf J Ludwig; Dana Tzur Bitan; Arnon D Cohen
Journal:  Acta Derm Venereol       Date:  2021-09-03       Impact factor: 3.875

5.  Therapy of autoimmune bullous diseases.

Authors:  Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

Review 6.  Management of pemphigus.

Authors:  Benjamin S Daniel; Dedee F Murrell
Journal:  F1000Prime Rep       Date:  2014-05-06

Review 7.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

8.  A randomised clinical trial to assess the adjuvant potential of methotrexate to corticosteroids in mucosal or limited mucocutaneous pemphigus vulgaris.

Authors:  Khimit Jain; Vishal Thakur; Sanjeev Handa; Neha Thakur; Naresh Sachdeva; Rahul Mahajan; Dipankar De
Journal:  Sci Rep       Date:  2022-05-09       Impact factor: 4.996

Review 9.  Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review.

Authors:  Faith A P Zeng; Anna Wilson; Tabrez Sheriff; Dedee F Murrell
Journal:  JAAD Int       Date:  2022-08-07

Review 10.  Emerging treatment options for the management of pemphigus vulgaris.

Authors:  Khalaf Kridin
Journal:  Ther Clin Risk Manag       Date:  2018-04-27       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.